A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sinocelltech Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Voluntarily sign the informed consent form (ICF);
2. ECOG 0-1;
3. Survival duration more than 3 months;
4. Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) that is not amenable to complete surgical resection and cannot receive curative concurrent/sequential chemoradiotherapy;
5. Without AGA: Have experienced disease progression during or after prior treatment with PD-(L)1 inhibitors and chemotherapy.With AGA: Must have received adequate targeted therapy; EGFR-positive patients must have received prior treatment with PD-(L)1/VEGF bispecific antibody and/or TROP-2 ADC;
6. At least one measurable non-brain lesion according to RECIST v1.1;
7. Adequate major organ function.
You may not be if
1. Histologically or cytologically confirmed presence of small cell carcinoma components;
2. Prior treatment with docetaxel;
3. Symptomatic central nervous system (CNS) metastases;
4. Received the last dose of prior systemic anti-tumor therapy within 4 weeks before the first dose of study drug;
5. Imaging findings at screening show tumor invasion into major blood vessels or surrounding vital organs, or the presence of a risk of esophagotracheal or esophagopleural fistula, which the investigator assesses as unsuitable for enrollment;
6. History of hypertensive crisis or hypertensive encephalopathy; presence of uncontrolled hypertension despite medical therapy;
7. Presence of any active autoimmune disease or history of autoimmune disease with anticipated risk of relapse;
8. Bleeding tendency, high risk of bleeding, or coagulation disorders;
9. Diagnosis of another malignancy;
10. Severe infection, active infection, active tuberculosis, positive HIV antibody, active hepatitis B or hepatitis C, or known active syphilis prior to the first dose;
11. Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
12. History of non-infectious pneumonitis that required systemic corticosteroid therapy, or current presence of interstitial lung disease;
13. Prior history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
14. Known hypersensitivity to any component of the study drug; known hypersensitivity to taxanes; or history of severe hypersensitivity reaction to any other monoclonal antibody;
15. Pregnant or breastfeeding women;
16. Any other condition that the investigator considers inappropriate for enrollment.
Clareo Health | A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
